| Literature DB >> 36005067 |
Mélanie Tantot1, Vincent Le Moal1, Éric Mévellec1, Isabelle Nouy-Trollé1, Emmanuelle Lemoine-Josse1, Florent Besnier2, Thibaut Guiraud1.
Abstract
Non-specific chronic low back pain (NSCLBP) is defined as a complex disorder involving structural, biomechanical, cognitive, psychological, social, and lifestyle factors. Non-pharmacological approaches such as exercise and physical therapy have been proposed in first-line treatments, along with psychological follow-up and pain medication if needed. Our objective was to evaluate the effectiveness of an intensive rehabilitation program with HUBER (a multi-axis motorized platform equipped with force sensors, allowing patients to perform physical exercises in an isometric mode) on the spine flexion-to-extension ratio at 60 and 120°/s, pain, and trunk flexibility in individuals with NSCLBP. Twelve participants underwent a clinical evaluation including isokinetic spine strength and participated in a 6-week rehabilitation program with HUBER 360 Evolution. The main findings of this pilot study show that the flexor/extensor ratios at 60°, the flexibility of the hamstring and quadriceps, and muscular endurance of the trunk, disability, and quality of life were significantly improved at the end of the rehabilitation program (p < 0.05). Low back pain and analgesic medication were also reduced. Exercising with the HUBER Platform seems to be effective in managing NSCLBP but a randomized study with a larger sample size and a control group is necessary.Entities:
Keywords: low back pain; physical activity; rehabilitation
Year: 2022 PMID: 36005067 PMCID: PMC9406810 DOI: 10.3390/clinpract12040064
Source DB: PubMed Journal: Clin Pract ISSN: 2039-7275
Figure 1The HUBER 360 ® Evolution Platform. Coordination and muscle-strengthening exercise on the HUBER Platform. The platform moves back and forth and left and right. The patient must push on the handles with the arms, but the movement starts from the legs with the core engaged. The target is represented by a blue gauge on the screen.
Clinical Characteristics at Baseline and After the 6-week Intervention Program.
| HUB |
| Cohen’s d | ||
|---|---|---|---|---|
| Pre | Post | |||
| Age | 42.92 ± 9.17 | |||
| Sex; | 3 (25%) | |||
| Weight (kg) | 89.00 ± 23.78 | |||
| Heigh (cm) | 175.33 ± 6.85 | |||
| Body mass index (kg·m2) | 29.08 ± 8.07 | |||
| Pain visual analog scale (/10) | 3.70 ± 1.92 | 1.65 ± 1.28 | 0.0110 | 1.26 |
| Oswestry Disability Index | 29.83 ± 9.32 | 14.00 ± 8.36 | 0.0000 | 1.79 |
| FABQ * work | 73.11 ± 18.58 | 50.63 ± 32.04 | 0.0244 | 0.86 |
| FABQ * physical activity | 54.12 ± 23.06 | 27.43 ± 15.74 | 0.0275 | 1.35 |
| Iso Fr 60 (Nm) | 197.77 ± 99.81 | 209.17 ± 64.46 | 0.1823 | 0.14 |
| Iso Exr 60 (Nm) | 209.03 ± 114.12 | 301.33 ± 99.85 | 0.0000 | 0.86 |
| Ratio 60 | 104.70 ± 25.03 | 71.25 ± 14.72 | 0.0002 | 1.63 |
| Peak Torque moy./kg 60 (Nm/kg) | 2.12 ± 0.95 | 3.27 ± 0.92 | 0.0000 | 1.24 |
| Iso Fr 120 | 177.83 ± 80.90 | 212.43 ± 82.52 | 0.0006 | 0.42 |
| Iso Exr 120 | 210.76 ± 112.48 | 267.32 ± 76.60 | 0.0149 | 0.59 |
| Ratio 120 | 89.78 ± 23.68 | 78.25 ± 11.27 | 0.1487 | 0.62 |
| Peak Torque moy./kg 120 (Nm/kg) | 2.32 ± 0.98 | 3.01 ± 0.77 | 0.0090 | 0.78 |
| VO2max (mL. kg. min) | 31.80 ± 5.00 | 34.80 ± 5.23 | 0.0076 | 0.59 |
| Lumbar mobility and flexibility | Pre | Post |
| Cohen’s d |
| Dual Inclinometry Flex° (°) | 23.33 ± 8.88 | 19.17 ± 5.57 | 0.0854 | - |
| Dual Inclinometry Ext° (°) | 18.25 ± 12.59 | 23.33 ± 13.54 | 0.147 | - |
| DI Inclination Right (°) | 14.17 ± 7.93 | 17.92 ± 6.56 | 0.095 | - |
| DI Inclination Left (°) | 14.08 ± 8.32 | 17.92 ± 5.82 | 0.1499 | - |
| Modified Thomas test Right (°) | 18.06 ± 10.58 | 13.75 ± 9.32 | 0.1485 | - |
| Modified Thomas test Left (°) | 13.89 ± 7.73 | 13.75 ± 11.10 | 0.9647 | - |
| Popliteal angle test Right (°) | 138.06 ± 11.99 | 146.25 ± 9.56 | 0.0166 | 0.76 |
| Popliteal angle test Left (°) | 136.53 ± 12.28 | 145.83 ± 8.75 | 0.0012 | 0.87 |
| Distance heel–buttocks Right (cm) | 10.67 ± 6.95 | 4.42 ± 4.03 | 0.0012 | 1.10 |
| Distance heel–buttocks Left (cm) | 9.67 ± 7.88 | 5.58 ± 4.91 | 0.0278 | 0.62 |
| Biering–Sorensen test (s) | 67.67 ± 38.49 | 113.83 ± 56.33 | 0.0102 | 0.96 |
| Shirado–Ito test (s) | 66.67 ± 37.00 | 106.33 ± 59.71 | 0.0051 | 0.80 |
| Shirado/Biering ratio | 1.28 ± 1.12 | 1.05 ± 0.64 | 0.3228 | |
| Killy test (s) | 38.50 ± 22.89 | 225.92 ± 229.21 | 0.0022 | 1.15 |
| Pharmacological treatments (number of patients concerned with each class of therapy) | ||||
| Analgesic step 1/2/3 * | 6/3/3 | 4/1/1 | ||
| Antidepressant | 2 | 2 | ||
| Antiepileptic | 1 | 1 | ||
| ACE * inhibitors | 1 | 0 | ||
* ACE: Angiotensin-converting enzyme (ACE) inhibitors; FABQ: Fear and Avoidance Belief Questionnaire. Analgesic steps from 1 to 3 refer to the WHO Pain Ladder with Pain Management Guidelines (step 1: Mild Pain (1–3/10); step 2: Moderate Pain (4–6/10); step 3: Severe Pain (7–10/10).
Figure 2Violin box representing change between pre and post intervention data. The black dotted lines represent the median and the interquartile range.